Ishita Drugs & Indus opened higher at ₹72.72, compared with its previous close of ₹72.62. In the last trading session on 12 Nov 2026, the stock traded between ₹72.71 and ₹72.72, with an average traded price of ₹72.71. It showed a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in Ishita Drugs & Indus is now worth
₹ 15,876.00
Giving a profit of
₹ 5,876.00 (58.76%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+0.09 (+0.12%)
Day High
₹72.72
Day Low
₹72.71
Day Open
₹72.72
Prev Close
₹72.62
Volume
7
Value Traded
₹0.00 Cr
1W Return
0.97%
1M Return
-4.33%
3M Return
-3.05%
6M Return
-12.40%
1Y Return
3.87%
Market Cap (₹ Cr.)
22
PE Ratio
30.00
PB Ratio
1.82
Dividend Yield
-
ROE
6.73%
ROCE
9.81%
Book Value (₹)
40.00
Face Value (₹)
10.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
0.97%
6 Weeks
-
1 Month
-4.33%
3 Months
-3.05%
9 Months
-1.73%
No data available.
Ishita Drugs Q2FY27 Results: Net profit up 12% YoY to ₹16.08 lakh
Net profit rose 12.21% YoY to ₹16.08 lakh in Q2FY27. Revenue from operations declined 1.14% YoY to ₹303.31 lakh. Other income surged 136.77% YoY to ₹15.84 lakh. Company spent ₹488 lakh on facility upgradation for Schedule M compliance.
9 days agoIshita Drugs re-appoints Abha Agrawal as director post-75 age limit
Mrs. Abha Agrawal re-appointed as director with 86.92% votes despite age cap. Jaymin Shah & Associates re-appointed as statutory auditors for FY27. FY26 financial statements adopted with 99.99% support from shareholders. Related party transactions with Ishita Pharmaceuticals approved by majority.
1mo agoIshita Drugs closes trading window until Q2FY27 results declaration
Trading window closed from October 1, 2026. Restriction lasts until 48 hours after Q2FY27 results. Action complies with SEBI (Prohibition of Insider Trading) Regulations, 2015.
1mo agoIshita Drugs enters ₹11.75 crore loan deal with HDFC Bank for facility upgrade
Ishita Drugs & Industries entered a ₹11.75 crore loan agreement with HDFC Bank. Funds will finance facility upgradation at Sanand plant for Revised Schedule M compliance. Facility comprises ₹9.75 crore term loan and ₹2 crore working capital line. First charge created on immovable and movable assets at the Sanand manufacturing unit. Transaction is not a related party deal; no special rights granted to lender.
1mo agoIshita Drugs sets Sep 30 AGM for related-party deals, director re-appointment
Ishita Drugs schedules 33rd AGM for September 30, 2026, at Hotel Krsna Lila in Sanand, Gujarat. Key agenda includes approval of related-party transactions exceeding 10% of annual turnover. Special business involves re-appointment of promoter director Mrs. Abha Agrawal after she turns 75. E-voting window opens on September 27 and closes on September 29, 2026. Company dispatched physical notices to 3,069 shareholders without registered email addresses.
2mo agoIshita Drugs & Industries Q1 Results: Net profit falls 24% YoY to ₹23 lakh
Ishita Drugs and Industries Limited posted a net profit of ₹23.02 lakh for Q1FY26, a 24% decline from ₹30.23 lakh in Q1FY25. Revenue from operations fell to ₹314.53 lakh from ₹540.05 lakh year-on-year. The Board approved the re-appointment of Mrs. Abha Agrawal as a director and accepted revised remuneration for CFO Mr. Sumit Agrawal. The company is investing in facility upgrades to meet Revised Schedule M compliance, having spent ₹435 lakh so far.
3mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,898.30 | +0.71% | ₹4,55,465.76 | 41.20 | +9.60% | |
| ₹11,502.50 | +0.15% | ₹3,05,355.23 | 90.40 | +76.42% | |
| ₹4,689.50 | -0.80% | ₹1,78,373.51 | 85.50 | +22.61% | |
| ₹2,434.80 | +1.45% | ₹1,31,555.22 | 97.10 | +146.13% | |
| ₹1,204.60 | -0.12% | ₹1,20,159.31 | 28.00 | +26.61% | |
| ₹1,388.90 | +0.17% | ₹1,15,928.74 | 42.00 | +12.96% | |
| ₹1,409.30 | +0.07% | ₹1,13,851.49 | 39.90 | -7.24% | |
| ₹2,666.00 | +1.04% | ₹1,10,117.82 | 48.10 | +17.44% | |
| ₹1,816.20 | +0.50% | ₹1,04,500.13 | 26.00 | +53.45% | |
| ₹2,020.80 | +0.29% | ₹92,409.16 | 17.60 | -0.64% | |
| ₹2,641.50 | -0.69% | ₹74,549.65 | 51.60 | +42.95% | |
| ₹5,187.50 | -2.16% | ₹62,024.34 | 30.50 | -10.06% |
An investment of ₹10,000 made 5 years ago in Ishita Drugs & Indus is now worth
₹ 15,876.00
Giving a profit of
₹ 5,876.00 (58.76%)
Note: Past profits do not guarantee future returns.
